Birdwatch Note
2023-11-02 17:09:58 UTC - NOT_MISLEADING
This metaanalysis of are 99 studies supports the use of Ivermectin for COVID-19. https://c19ivm.org/meta.html
Written by 1B1CB1F89D1E81632D4FDC6BA92128E495C177985E7EF4E0D3550B57B56A0E90
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1720121889492717599
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1720126114415198318
- noteId - 1720126114415198318
- participantId -
- noteAuthorParticipantId - 1B1CB1F89D1E81632D4FDC6BA92128E495C177985E7EF4E0D3550B57B56A0E90 Participant Details
- createdAtMillis - 1698944998730
- tweetId - 1720121889492717599
- classification - NOT_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 1
- trustworthySources - 1
- summary
- This metaanalysis of are 99 studies supports the use of Ivermectin for COVID-19. https://c19ivm.org/meta.html
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2023-11-02 17:09:58 UTC (1698944998730) |
1969-12-31 23:59:59 UTC (-1) |
2023-11-04 03:04:16 UTC (1699067056450) |
NEEDS_MORE_RATINGS | 1969-12-31 23:59:59 UTC (-1) |
Note Ratings
| rated at | rated by | |
| 2023-11-03 17:43:26 -0500 | Rating Details | |
| 2023-11-03 17:35:13 -0500 | Rating Details | |
| 2023-11-03 12:42:02 -0500 | Rating Details | |
| 2023-11-03 11:11:05 -0500 | Rating Details | |
| 2023-11-03 09:26:57 -0500 | Rating Details | |
| 2023-11-03 08:26:20 -0500 | Rating Details | |
| 2023-11-03 08:03:39 -0500 | Rating Details | |
| 2023-11-03 06:47:57 -0500 | Rating Details | |
| 2023-11-03 05:54:28 -0500 | Rating Details | |
| 2023-11-03 05:16:49 -0500 | Rating Details | |
| 2023-11-03 05:11:38 -0500 | Rating Details | |
| 2023-11-03 04:57:19 -0500 | Rating Details | |
| 2023-11-03 02:32:14 -0500 | Rating Details | |
| 2023-11-03 01:33:23 -0500 | Rating Details | |
| 2023-11-03 01:02:58 -0500 | Rating Details | |
| 2023-11-03 00:36:25 -0500 | Rating Details | |
| 2023-11-02 23:10:47 -0500 | Rating Details | |
| 2023-11-02 22:00:28 -0500 | Rating Details | |
| 2023-11-02 21:21:19 -0500 | Rating Details | |
| 2023-11-02 21:13:19 -0500 | Rating Details | |
| 2023-11-02 19:50:35 -0500 | Rating Details | |
| 2023-11-02 19:35:23 -0500 | Rating Details | |
| 2023-11-02 19:22:31 -0500 | Rating Details | |
| 2023-11-02 19:12:58 -0500 | Rating Details | |
| 2023-11-02 19:08:44 -0500 | Rating Details | |
| 2023-11-02 19:06:21 -0500 | Rating Details | |
| 2023-11-02 18:23:16 -0500 | Rating Details | |
| 2023-11-02 17:43:03 -0500 | Rating Details | |
| 2023-11-02 17:40:41 -0500 | Rating Details | |
| 2023-11-02 17:33:04 -0500 | Rating Details | |
| 2023-11-02 17:07:31 -0500 | Rating Details | |
| 2023-11-02 15:59:00 -0500 | Rating Details | |
| 2023-11-02 15:39:16 -0500 | Rating Details | |
| 2023-11-02 15:29:15 -0500 | Rating Details | |
| 2023-11-02 15:27:31 -0500 | Rating Details | |
| 2023-11-02 15:18:16 -0500 | Rating Details | |
| 2023-11-02 14:55:10 -0500 | Rating Details | |
| 2023-11-02 14:37:30 -0500 | Rating Details | |
| 2023-11-02 13:59:14 -0500 | Rating Details | |
| 2023-11-02 13:49:56 -0500 | Rating Details | |
| 2023-11-02 13:35:57 -0500 | Rating Details | |
| 2023-11-02 13:34:07 -0500 | Rating Details | |
| 2023-11-02 13:14:54 -0500 | Rating Details | |
| 2023-11-02 13:13:09 -0500 | Rating Details | |
| 2023-11-02 12:56:09 -0500 | Rating Details | |
| 2023-11-04 18:44:43 -0500 | Rating Details | |
| 2023-11-04 17:59:46 -0500 | Rating Details | |
| 2023-11-04 16:23:00 -0500 | Rating Details | |
| 2023-11-04 16:01:31 -0500 | Rating Details | |
| 2023-11-04 13:41:51 -0500 | Rating Details | |
| 2023-11-04 12:12:45 -0500 | Rating Details | |
| 2023-11-04 11:43:18 -0500 | Rating Details | |
| 2023-11-04 11:39:24 -0500 | Rating Details | |
| 2023-11-04 11:26:13 -0500 | Rating Details | |
| 2023-11-04 11:26:13 -0500 | Rating Details | |
| 2023-11-04 11:19:58 -0500 | Rating Details | |
| 2023-11-04 11:12:53 -0500 | Rating Details | |
| 2023-11-03 21:22:40 -0500 | Rating Details | |
| 2023-11-04 23:55:57 -0500 | Rating Details | |
| 2023-11-13 09:26:59 -0600 | Rating Details | |
| 2023-11-17 16:18:15 -0600 | Rating Details | |
| 2023-11-27 04:32:04 -0600 | Rating Details | |
| 2024-02-24 02:13:51 -0600 | Rating Details | |
| 2024-08-02 15:16:36 -0500 | Rating Details | |
| 2024-08-02 14:44:14 -0500 | Rating Details |